Open AccessClinical outcomes following salvage gamma knife radiosurgery for recurrent glioblastoma
Author(s) -
Erik W. Larson,
Halloran E Peterson,
Wayne T. Lamoreaux,
Alexander R. Mackay,
Robert K. Fairbanks,
Jason A. Call,
Jonathan D. Carlson,
Bowen Ling,
John J. Demakas,
Barton S. Cooke,
Christopher M. Lee
Publication year - 2014
Publication title -
world journal of clinical oncology
Language(s) - Uncategorized
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v5.i2.142
Subject(s) - medicine , salvage therapy , radiosurgery , bevacizumab , progression free survival , radiation therapy , adverse effect , surgery , oncology , overall survival , chemotherapy
Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor with a survival prognosis of 14-16 mo for the highest functioning patients. Despite aggressive, multimodal upfront therapies, the majority of GBMs will recur in approximately six months. Salvage therapy options for recurrent GBM (rGBM) are an area of intense research. This study compares recent survival and quality of life outcomes following Gamma Knife radiosurgery (GKRS) salvage therapy. Following a PubMed search for studies using GKRS as salvage therapy for malignant gliomas, nine articles from 2005 to July 2013 were identified which evaluated rGBM treatment. In this review, we compare Overall survival following diagnosis, Overall survival following salvage treatment, Progression-free survival, Time to recurrence, Local tumor control, and adverse radiation effects. This report discusses results for rGBM patient populations alone, not for mixed populations with other tumor histology grades. All nine studies reported median overall survival rates (from diagnosis, range: 16.7-33.2 mo; from salvage, range: 9-17.9 mo). Three studies identified median progression-free survival (range: 4.6-14.9 mo). Two showed median time to recurrence of GBM. Two discussed local tumor control. Six studies reported adverse radiation effects (range: 0%-46% of patients). The greatest survival advantages were seen in patients who received GKRS salvage along with other treatments, like resection or bevacizumab, suggesting that appropriately tailored multimodal therapy should be considered with each rGBM patient. However, there needs to be a randomized clinical trial to test GKRS for rGBM before the possibility of selection bias can be dismissed.